Insulet Corporation

PODD Healthcare Medical Devices

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

141.10 2.33 +1.68%
Market cap
$9.6B
P/E
26.4×
Fwd P/E
24.7×
Dividend yield
—
F-score
6/9
Altman Z
9.09
Beneish M
−2.59
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

88.21 81.21 48.80 28.46
P/S ratio
8.61 7.38 5.06 3.46
P/FCF ratio
53.31 57.15 37.87 39.72
P/Operating CF
172.83 109.09 129.05 119.35
P/B ratio
15.69 13.20 11.27 7.42
EV/Sales
8.72 7.47 5.22 3.59
EV/EBITDA
41.91 35.85 25.17 17.83
EV/FCF
53.94 57.81 39.08 41.28
Current Ratio
2.87 2.81 2.49 2.48
Net Debt/EBITDA
1.84 1.37 3.15 2.64
Debt/Equity
0.73 0.63 0.73 0.67
Earnings Yield
1.13% 1.23% 2.05% 3.51%
Free Cash Flow Yield
1.88% 1.75% 2.64% 2.52%
Free Cash Flow per Share
1.34 0.48 1.23 0.74
Book value per Share
19.67 21.54 18.61 20.52
Free Cash Flow
94.60 33.90 86.00 51.10
EV/EBIT
50.30 42.69 29.88 21.26
Other line items

Show all line items

Columns are period end dates